McKesson Slides as GLP-1 Fears Reshape Pharma Logistics Landscape

Janus Henderson Investors' "Global Sustainable Equity Fund" navigated a robust equity rally in the second quarter of 2026, yet the fund faced notable headwinds from healthcare giant McKesson Corporation (NYSE:MCK), highlighting a sector-wide derating in drug distribution. While the fund outperformed its benchmarks with a 16.17% return—driven largely by an overweight position in AI infrastructure—the underperformance of McKesson served as a critical signal regarding the structural vulnerabilities facing pharmaceutical supply chains amidst the rise of weight-loss drugs.

GLP-1 Shockwaves and Margin Compression

McKesson's share price decline is not an isolated incident but a symptom of broader shifts in healthcare reimbursement and investor sentiment. Janus Henderson identified the primary drivers behind this derating as follows:

■Concerns over GLP-1 cash-pay models disrupting traditional reimbursement flows.

■A capital rotation into insurers, potentially bypassing traditional distributors.

■Rising apprehension regarding specialty pharmacy exposure ahead of a massive wave of loss-of-exclusivity events over the next five years.

■Fears that lower drug pricing dynamics could inevitably compress distributor margins.

As of July 15, 2026, McKesson shares closed at $796.35, reflecting a market capitalization of $93.23 billion. Despite a solid one-month return of 9.60%, the stock’s 52-week performance lagged at 15.82%, weighed down by these systemic concerns.

Capital Flows and Hedge Fund Positioning

Data on institutional ownership reveals a nuanced picture of risk appetite. McKesson is not currently among the top 40 most popular stocks among hedge funds heading into 2026, yet interest remains resilient. Our database indicates that 73 hedge fund portfolios held McKesson at the end of Q1 2026, up slightly from 72 in the previous quarter. Fundamentally, the company remains robust; diluted earnings per share reached $11.69 in fiscal Q4 2026, a 16% increase year-over-year. Janus Henderson maintains its thesis, viewing McKesson as a leading player with defensive growth characteristics, scale advantages, and durable customer relationships. However, the fund suggests that certain AI stocks currently offer a better risk-reward profile compared to the pharmaceutical distribution giant.

Markets are currently pricing in a structural overhaul of drug logistics, and the McKesson slide reflects classic margin compression fears in a shifting risk-off environment. The GLP-1 revolution is redesigning the supply chain, affecting not just biotech firms but the entire distribution middleware. While hedge funds maintaining their positions signals confidence in the company's fundamental moat, the sector-wide multiple compression suggests a liquidity drain towards more dynamic sectors like AI infrastructure. Investors should monitor this rotation closely as the battle between defensive cash flows and growth intensifies.